MAR 3 1 ZEE TO A TO THE TRANSPORT

4.3.0

PATENT Moore

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ronny van't Oever, et al.

Serial No.: 09/874,493

Filed: June 5, 2001

FOR RED BLOOD CELL DIFFERENTIATION ON A CELL-BY-CELL BASIS, AND

SIMULTANEOUS ANALYSIS OF WHITE BLOOD CELL DIFFERENTIATION

Attorney Docket No.: 6811.US.O1

Group Art Unit: 2876

CERTIFICATE OF MAILING (37 CFR 1.8(a)):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents Washington, D.C. 20231,

Kimberly

RESPONSE

Commissioner for Patents Washington DC 20231

Dear Sir:

This Response is being submitted in connection with the second Office Action mailed December 31, 2002 in the above-captioned application. Reconsideration of the application in view of the following remarks is respectfully requested.

REMARKS

Claims 1-21 are pending. Claims 1- 12 and 21 are allowed. Claims 13 -20 stand rejected under 35 U.S.C. § 103(a).

Rejections under 35 U.S.C. § 103(a)

1) Claims 13 - 15 and 19 - 20 stand rejected under 35 U.S.C. § 103 as being obvious over Tycko, US Patent 5,194,909 (hereinafter "'909 patent") in view of Altendorf, US Patent 6,067,157 (hereinafter "'157 patent"). Applicants respectfully traverse the rejection.

To establish a prima facie obviousness under § 103(a), the Examiner must identify, from a source other than Applicant's own specification both (i) a suggestion to